Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Anika Therapeutics (ANIK) EBIT (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed EBIT for 16 consecutive years, with $646000.0 as the latest value for Q4 2025.

  • On a quarterly basis, EBIT fell 97.68% to $646000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$11.1 million, a 147.18% decrease, with the full-year FY2025 number at -$11.1 million, down 116.64% from a year prior.
  • EBIT was $646000.0 for Q4 2025 at Anika Therapeutics, up from -$3.2 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $27.8 million in Q4 2024 to a low of -$12.6 million in Q1 2023.
  • A 5-year average of $975000.0 and a median of -$2.9 million in 2024 define the central range for EBIT.
  • Peak YoY movement for EBIT: soared 279.8% in 2022, then crashed 3891.36% in 2025.
  • Anika Therapeutics' EBIT stood at -$9.1 million in 2021, then skyrocketed by 279.8% to $16.4 million in 2022, then surged by 50.59% to $24.7 million in 2023, then rose by 12.61% to $27.8 million in 2024, then crashed by 97.68% to $646000.0 in 2025.
  • Per Business Quant, the three most recent readings for ANIK's EBIT are $646000.0 (Q4 2025), -$3.2 million (Q3 2025), and -$4.2 million (Q2 2025).